2021
DOI: 10.1111/jth.15214
|View full text |Cite
|
Sign up to set email alerts
|

Clinical history of cancer‐associated splanchnic vein thrombosis

Abstract: Background: Cancer represents a risk factor for splanchnic vein thrombosis (SVT) and usual site venous thromboembolism (VTE). Objectives: To compare characteristics and outcomes of patients with cancerassociated SVT and usual site VTE. Patients/Methods: Patients with solid cancer and SVT were enrolled in an international, prospective registry between May 2008 and January 2012. The comparison cohort included (1:1 ratio) patients with solid cancer and usual site VTE treated at two thrombosis centers who had a mi… Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
2
2
1

Citation Types

1
12
0

Year Published

2021
2021
2025
2025

Publication Types

Select...
8

Relationship

2
6

Authors

Journals

citations
Cited by 16 publications
(13 citation statements)
references
References 41 publications
1
12
0
Order By: Relevance
“…We also explored the effectiveness and safety of anticoagulant therapy in high-risk subgroups such as those with liver cirrhosis, solid cancers, or myeloproliferative neoplasms. 24, 28, 32, 33 Our findings seem reassuring and suggest a lower risk of recurrent VTE, major bleeding, and all-cause mortality during anticoagulant therapy compared with off-treatment periods. These results support the recommendations of recent guidelines to promptly start anticoagulation for acute SVT irrespective of underlying risk factors in the absence of major contraindications.…”
Section: Discussionsupporting
confidence: 53%
See 1 more Smart Citation
“…We also explored the effectiveness and safety of anticoagulant therapy in high-risk subgroups such as those with liver cirrhosis, solid cancers, or myeloproliferative neoplasms. 24, 28, 32, 33 Our findings seem reassuring and suggest a lower risk of recurrent VTE, major bleeding, and all-cause mortality during anticoagulant therapy compared with off-treatment periods. These results support the recommendations of recent guidelines to promptly start anticoagulation for acute SVT irrespective of underlying risk factors in the absence of major contraindications.…”
Section: Discussionsupporting
confidence: 53%
“…These results support the recommendations of recent guidelines to promptly start anticoagulation for acute SVT irrespective of underlying risk factors in the absence of major contraindications. 3, 6, 32 Sixty-one percent of recurrent VTEs occurred outside the splanchnic venous circulation, most often in patients with persistent risk factors. The latter have a chronic procoagulant state and, as for usual-site VTE, may warrant long-term anticoagulation.…”
Section: Discussionmentioning
confidence: 99%
“… 41 A study comparing cancer-associated splanchnic vein thrombosis versus usual site VTE noted that the most common locations of cancer were hepatobiliary and pancreatic in the former and gastrointestinal in the latter. 42 …”
Section: Cancer-associated Thrombosismentioning
confidence: 99%
“…41 A study comparing cancer-associated splanchnic vein thrombosis versus usual site VTE noted that the most common locations of cancer were hepatobiliary and pancreatic in the former and gastrointestinal in the latter. 42 Cerebral vein thrombosis can also be the first clinical manifestation of solid cancers, especially brain tumours, 43 or myeloproliferative neoplasms. The presence of the Janus Kinase 2 (JAK2) V617F mutation, commonly found in myeloproliferative neoplasms, has been reported in 6.6% of patients with cerebral vein thrombosis.…”
Section: Cancer-associated Thrombosis Epidemiology Of Cancer-associat...mentioning
confidence: 99%
“…20 The vast majority of tumors is of digestive location, with a preponderance of hepatocellular carcinoma, colon, pancreas, and gastric tumors. 21 Furthermore, in the 5 years after a diagnosis of SVT, solid tumors (in particular hepatocellular carcinoma and pancreas cancer) are diagnosed in approximately 15% of patients, corresponding to a fourfold relative increase compared with the general population. 22 Myeloproliferative neoplasms cause approximately 8% of SVT, and are particularly associated with Budd-Chiari syndrome (thrombosis of the suprahepatic veins), as highlighted by a 40% prevalence of the JAK2V617F mutation in such cases.…”
Section: Which Specific Situations May Trigger An Extensive Screeningmentioning
confidence: 99%